Thinly traded nano cap Oragenics (OGEN +37.9%) is up in early trade on a healthy 15x surge in volume. Shares have rallied 86% in two days.
No particular news accounts for the action although a key upcoming event (Q2) is the release of preliminary data from a Phase 2 clinical trial assessing lead candidate AG013 in oral mucositis.
At the end of December, it had $6.2M in quick assets. Operations consumed $6.4M in 2017 so a capital raise will be needed at some point.
Subscribe for full text news in your inbox